Anifrolumab, Anifrolumab Placebo
D3463C00003, JASMINE
Phase 3 small_molecule active
Quick answer
Anifrolumab, Anifrolumab Placebo for Polymyositis or dermatomyositis according to 2017 EULAR / ACR classification criteria is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca AB
- Indication
- Polymyositis or dermatomyositis according to 2017 EULAR / ACR classification criteria
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active